256 related articles for article (PubMed ID: 1846327)
1. Defective control of Epstein-Barr virus-infected B cell growth in patients with X-linked lymphoproliferative disease.
Yasuda N; Lai PK; Rogers J; Purtlo DT
Clin Exp Immunol; 1991 Jan; 83(1):10-6. PubMed ID: 1846327
[TBL] [Abstract][Full Text] [Related]
2. Immunoregulatory T cells in males vulnerable to Epstein-Barr virus with the X-linked lymphoproliferative syndrome.
Lai PK; Yasuda N; Purtilo DT
Am J Pediatr Hematol Oncol; 1987; 9(2):179-82. PubMed ID: 3035958
[TBL] [Abstract][Full Text] [Related]
3. SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease.
Sharifi R; Sinclair JC; Gilmour KC; Arkwright PD; Kinnon C; Thrasher AJ; Gaspar HB
Blood; 2004 May; 103(10):3821-7. PubMed ID: 14726378
[TBL] [Abstract][Full Text] [Related]
4. Interferon-gamma in a family with X-linked lymphoproliferative syndrome with acute Epstein-Barr virus infection.
Okano M; Thiele GM; Kobayashi RH; Davis JR; Synovec MS; Grierson HL; Jaffe HS; Purtilo DT
J Clin Immunol; 1989 Jan; 9(1):48-54. PubMed ID: 2539385
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus-infected B cells of males with the X-linked lymphoproliferative syndrome stimulate and are susceptible to T-cell-mediated lysis.
Jäger M; Benninger-Döring G; Prang N; Sylla BS; Laumbacher B; Wank R; Wolf H; Schwarzmann F
Int J Cancer; 1998 May; 76(5):694-701. PubMed ID: 9610728
[TBL] [Abstract][Full Text] [Related]
6. Cell-mediated immunity to Epstein-Barr virus (EBV) and natural killer (NK)-cell activity in the X-linked lymphoproliferative syndrome.
Harada S; Bechtold T; Seeley JK; Purtilo DT
Int J Cancer; 1982 Dec; 30(6):739-44. PubMed ID: 6298119
[TBL] [Abstract][Full Text] [Related]
7. X-linked lymphoproliferative syndrome. Natural history of the immunodeficiency.
Sullivan JL; Byron KS; Brewster FE; Baker SM; Ochs HD
J Clin Invest; 1983 Jun; 71(6):1765-78. PubMed ID: 6306053
[TBL] [Abstract][Full Text] [Related]
8. Cellular immune defects to Epstein-Barr virus-determined antigens in young males.
Masucci MG; Szigeti R; Ernberg I; Masucci G; Klein G; Chessels J; Sieff C; Lie S; Glomstein A; Businco L; Henle W; Henle G; Pearson G; Sakamoto K; Purtilo DT
Cancer Res; 1981 Nov; 41(11 Pt 1):4284-91. PubMed ID: 6171337
[TBL] [Abstract][Full Text] [Related]
9. Expression of Epstein-Barr virus-encoded proteins and B-cell markers in fatal infectious mononucleosis.
Falk K; Ernberg I; Sakthivel R; Davis J; Christensson B; Luka J; Okano M; Grierson HL; Klein G; Purtilo DT
Int J Cancer; 1990 Dec; 46(6):976-84. PubMed ID: 2174416
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the defects responsible for the impaired regulation of Epstein-Barr virus-induced B cell proliferation by rheumatoid arthritis lymphocytes. I. Diminished gamma interferon production in response to autologous stimulation.
Hasler F; Bluestein HG; Zvaifler NJ; Epstein LB
J Exp Med; 1983 Jan; 157(1):173-88. PubMed ID: 6294213
[TBL] [Abstract][Full Text] [Related]
11. The X-linked lymphoproliferative disease gene product SAP is expressed in activated T and NK cells.
Nagy N; Mattsson K; Maeda A; Liu A; Székely L; Klein E
Immunol Lett; 2002 Jun; 82(1-2):141-7. PubMed ID: 12008045
[TBL] [Abstract][Full Text] [Related]
12. Suppressive effect of human natural killer cells on Epstein-Barr virus-induced immunoglobulin synthesis.
Kuwano K; Arai S; Munakata T; Tomita Y; Yoshitake Y; Kumagai K
J Immunol; 1986 Sep; 137(5):1462-8. PubMed ID: 3018077
[TBL] [Abstract][Full Text] [Related]
13. Loss of circulating CD27+ memory B cells and CCR4+ T cells occurring in association with elevated EBV loads in XLP patients surviving primary EBV infection.
Malbran A; Belmonte L; Ruibal-Ares B; Baré P; Massud I; Parodi C; Felippo M; Hodinka R; Haines K; Nichols KE; de Bracco MM
Blood; 2004 Mar; 103(5):1625-31. PubMed ID: 14604960
[TBL] [Abstract][Full Text] [Related]
14. Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets.
Hislop AD; Palendira U; Leese AM; Arkwright PD; Rohrlich PS; Tangye SG; Gaspar HB; Lankester AC; Moretta A; Rickinson AB
Blood; 2010 Oct; 116(17):3249-57. PubMed ID: 20644117
[TBL] [Abstract][Full Text] [Related]
15. Defective generation of killer cells against spontaneously Epstein-Barr virus (EBV)-transformed autologous B cells in a fatal EBV infection.
Yanagisawa M; Kato M; Ikeno K; Kobayashi T; Miyagawa Y; Komiyama A; Akabane T
Clin Exp Immunol; 1987 May; 68(2):251-8. PubMed ID: 2820633
[TBL] [Abstract][Full Text] [Related]
16. Release of lymphokines after Epstein Barr virus infection in vitro. I. Sources of and kinetics of production of interferons and interleukins in normal humans.
Lotz M; Tsoukas CD; Fong S; Dinarello CA; Carson DA; Vaughan JH
J Immunol; 1986 May; 136(10):3636-42. PubMed ID: 3009608
[TBL] [Abstract][Full Text] [Related]
17. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
[TBL] [Abstract][Full Text] [Related]
18. Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro.
Wilson AD; Morgan AJ
J Virol; 2002 May; 76(10):5071-81. PubMed ID: 11967323
[TBL] [Abstract][Full Text] [Related]
19. Immune deficiency in the X-linked lymphoproliferative syndrome. I. Epstein-Barr virus-specific defects.
Harada S; Sakamoto K; Seeley JK; Lindsten T; Bechtold T; Yetz J; Rogers G; Pearson G; Purtilo DT
J Immunol; 1982 Dec; 129(6):2532-5. PubMed ID: 6292290
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of interleukin-4 induction and interferon-gamma inhibition of IgE secretion by Epstein-Barr virus-infected human peripheral blood B cells.
Thyphronitis G; Banchereau J; Heusser C; Tsokos GC; Levine AD; Finkelman FD
Cell Immunol; 1991 Apr; 133(2):408-19. PubMed ID: 1849800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
